BR112015029468A2 - sistema de dosagem não alimentar oralmente administrável; composição oralmente administrável; método para suplementar a nutrição de ferro em um indivíduo humano com necessidade do mesmo; método para mitigar um ou mais efeitos adversos gastrointestinais de ferro não absorvido - Google Patents

sistema de dosagem não alimentar oralmente administrável; composição oralmente administrável; método para suplementar a nutrição de ferro em um indivíduo humano com necessidade do mesmo; método para mitigar um ou mais efeitos adversos gastrointestinais de ferro não absorvido

Info

Publication number
BR112015029468A2
BR112015029468A2 BR112015029468A BR112015029468A BR112015029468A2 BR 112015029468 A2 BR112015029468 A2 BR 112015029468A2 BR 112015029468 A BR112015029468 A BR 112015029468A BR 112015029468 A BR112015029468 A BR 112015029468A BR 112015029468 A2 BR112015029468 A2 BR 112015029468A2
Authority
BR
Brazil
Prior art keywords
iron
orally administrable
mitigating
adverse effects
unabsorbed
Prior art date
Application number
BR112015029468A
Other languages
English (en)
Other versions
BR112015029468A8 (pt
Inventor
David Bortz Jonathan
Original Assignee
Amip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amip Llc filed Critical Amip Llc
Publication of BR112015029468A2 publication Critical patent/BR112015029468A2/pt
Publication of BR112015029468A8 publication Critical patent/BR112015029468A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

“sistema de dosagem não alimentar oralmente administrável; composição oralmente administrável; método para suplementar a nutrição de ferro em um indivíduo humano com necessidade do mesmo; método para mitigar um ou mais efeitos adversos gastrointestinais de ferro não absorvido.” resumo a presente invenção se refere a um sistema de dosagem oralmente administrável compreende (a) ferro em uma forma de um ou mais tipos de ferro fisiologicamente aceitáveis compostos e/ou complexos; e (b) um agente para mitigar um ou mais efeitos adversos gastrointestinais de ferro não absorvido, o referido agente compreendendo um ou ambos de um componente de zinco e um componente quelante, o referido componente de zinco se presente compreendendo um ou mais compostos e/ou complexos de zinco fisiologicamente aceitáveis, e o referido componente quelante, se presente compreendendo um composto quelante de íons formulado para liberação distal para o local principal de absorção de ferro no duodeno. 1/1
BR112015029468A 2013-06-06 2014-05-28 sistemas de dosagem oralmente administráveis, método para suplementar a nutrição de ferro em um indivíduo humano e métodos para mitigar um ou mais efeitos adversos gastrointestinais de ferro não absorvido BR112015029468A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361831879P 2013-06-06 2013-06-06
PCT/US2014/039738 WO2014197250A1 (en) 2013-06-06 2014-05-28 Iron supplement

Publications (2)

Publication Number Publication Date
BR112015029468A2 true BR112015029468A2 (pt) 2017-07-25
BR112015029468A8 BR112015029468A8 (pt) 2020-03-17

Family

ID=52005976

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015029468A BR112015029468A8 (pt) 2013-06-06 2014-05-28 sistemas de dosagem oralmente administráveis, método para suplementar a nutrição de ferro em um indivíduo humano e métodos para mitigar um ou mais efeitos adversos gastrointestinais de ferro não absorvido

Country Status (12)

Country Link
US (2) US11331287B2 (pt)
EP (1) EP3003328B1 (pt)
AU (1) AU2014275307B2 (pt)
BR (1) BR112015029468A8 (pt)
CA (1) CA2913413C (pt)
CR (1) CR20150665A (pt)
ES (1) ES2895044T3 (pt)
GT (1) GT201500328A (pt)
MX (1) MX2015016660A (pt)
PL (1) PL3003328T3 (pt)
WO (1) WO2014197250A1 (pt)
ZA (1) ZA201508363B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10653658B2 (en) 2015-08-11 2020-05-19 Akeso Biomedical, Inc. Biofilm inhibiting compositions enhancing weight gain in livestock
CN108024563A (zh) * 2015-08-11 2018-05-11 艾索生物医药公司 提高家畜中重量增加的生物膜抑制组合物
US11083738B2 (en) * 2017-09-28 2021-08-10 Natals, Inc. Dietary nutrient compositions
AU2018357350B2 (en) 2017-10-25 2023-09-21 Chiesi Farmaceutici S.P.A. Delayed release deferiprone tablets and methods of using the same
WO2020252014A1 (en) * 2019-06-10 2020-12-17 Ponce De Leon Health, Inc. Sustained-release compositions of alpha-ketoglutarate
US12016851B2 (en) * 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
US12016850B2 (en) * 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91047A (en) 1989-07-19 1993-06-10 Yissum Res Dev Co Zinc complexes for the treatment of free radical- induced diseases
US5536507A (en) * 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
US5516925A (en) 1994-08-23 1996-05-14 Albion International, Inc. Amino acid chelates having improved palatability
US6521247B1 (en) * 1999-08-13 2003-02-18 Warner Chilcott Laboratories Ireland Limited Dual iron containing nutritional supplement
US7160855B2 (en) * 2002-03-14 2007-01-09 Children's Hospital & Research Center At Oakland Enhancement of iron chelation therapy
US20060134227A1 (en) 2004-12-22 2006-06-22 Bortz Jonathan D Compositions including iron
CN1965697A (zh) 2005-11-15 2007-05-23 王健柏 营养补血保健饮用制品
US8007846B2 (en) 2006-01-18 2011-08-30 Albion International, Inc. Mixed amino acid/mineral compounds having improved solubility
TW200843802A (en) * 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
WO2009032699A1 (en) * 2007-08-29 2009-03-12 Drugtech Corporation Anti-proliferative combinations
WO2010136839A1 (en) 2009-05-29 2010-12-02 Carlo Ghisalberti Use of deferoxamine and related compounds in targeted delivery forms to treat an inflammatory bowel disease
CN101744120B (zh) 2009-12-25 2012-04-11 河北农业大学 乳仔猪微量元素预混料
CN102318764B (zh) 2011-08-30 2014-04-02 武汉天龙饲料有限公司 一种无抗仔猪教槽料及其制备方法
US20130209577A1 (en) * 2011-09-22 2013-08-15 Albion International, Inc. Buffered Upper GI Absorption Promoter

Also Published As

Publication number Publication date
ZA201508363B (en) 2017-09-27
US20140364491A1 (en) 2014-12-11
GT201500328A (es) 2017-12-14
CA2913413A1 (en) 2014-12-11
AU2014275307B2 (en) 2017-06-15
MX2015016660A (es) 2016-07-26
EP3003328B1 (en) 2021-07-28
WO2014197250A1 (en) 2014-12-11
EP3003328A4 (en) 2017-05-03
ES2895044T3 (es) 2022-02-17
CA2913413C (en) 2021-11-23
AU2014275307A1 (en) 2015-12-10
US11331287B2 (en) 2022-05-17
EP3003328A1 (en) 2016-04-13
PL3003328T3 (pl) 2022-01-24
CR20150665A (es) 2016-02-24
US20220233476A1 (en) 2022-07-28
BR112015029468A8 (pt) 2020-03-17

Similar Documents

Publication Publication Date Title
BR112015029468A2 (pt) sistema de dosagem não alimentar oralmente administrável; composição oralmente administrável; método para suplementar a nutrição de ferro em um indivíduo humano com necessidade do mesmo; método para mitigar um ou mais efeitos adversos gastrointestinais de ferro não absorvido
MY188749A (en) Compositions comprising a combination of nivolumab and ipilimumab
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
BR112015016997A2 (pt) composto, composição farmacêutica e método para o tratamento ou prevenção de câncer de mama
UA118255C2 (uk) Композиція, яка містить антитіло до cd38 і леналідомід
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
AU2016219643A1 (en) Pharmaceutical combination for the treatment of pain
BR112014031394A2 (pt) composições e métodos para absorção transmucosa
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
NZ702087A (en) Pharmaceutical compositions and treatment of mastitis
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
MY176246A (en) Compositions for oral administration of zoledronic acid or related compounds for treating disease
MX2013003635A (es) Compuestos de n-heteroarilo.
AR091351A1 (es) Formulaciones de bromocriptina, metodo para mejorar el control glucemico y metodo para la fabricacion
PH12015501783A1 (en) Pharmaceutical compositions for the treatment of helicobacter pylori
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
EA201991531A1 (ru) Способы лечения композициями линаклотида с отсроченным высвобождением
MX2015015667A (es) Composicion que comprende un complejo de (+)-catequina y aminoacido para el tratamiento y prevencion de cancer.
EA201291384A1 (ru) Терапевтические агенты 976
CL2020003153A1 (es) Composiciones antimicrobianas con agentes efervescentes (divisional de solicitud n° 03273-2016)
BR112018077440A2 (pt) uma composição para uso no tratamento de infecção de rotavírus
PH12015502560B1 (en) Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease
MX2016003763A (es) Terapia de combinacion con laquinimod para tratamiento de esclerosis multiple.
MA38426B1 (fr) Compositions antibiotiques de ceftolozane

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]